DK3551651T3 - Acylerede glp-1/glp-2-dobbeltagonister - Google Patents

Acylerede glp-1/glp-2-dobbeltagonister Download PDF

Info

Publication number: DK3551651T3
Authority: DK; Denmark
Prior art keywords: glp; acylated; dual antagonists; antagonists; dual
Prior art date: 2016-12-09

Application number

DK17832211.1T

Other languages

English (en)

Inventor

Jonathan Griffin

Alistair Vincent Gordon Edwards

Larsen Bjarne Due

Lise Giehm

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-09

Filing date

2017-12-11

Publication date

2024-05-13

2017-12-11 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2024-05-13 Application granted granted Critical

2024-05-13 Publication of DK3551651T3 publication Critical patent/DK3551651T3/da

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
230000009977 dual effect Effects 0.000 title 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK17832211.1T 2016-12-09 2017-12-11 Acylerede glp-1/glp-2-dobbeltagonister DK3551651T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201600757		2016-12-09
PCT/EP2017/082290 WO2018104561A1 (en)	2016-12-09	2017-12-11	Acylated glp-1/glp-2 dual agonists

Publications (1)

Publication Number	Publication Date
DK3551651T3 true DK3551651T3 (da)	2024-05-13

Family

ID=61005766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17832211.1T DK3551651T3 (da)	2016-12-09	2017-12-11	Acylerede glp-1/glp-2-dobbeltagonister

Country Status (18)

Country	Link
US (4)	US20190142904A1 (da)
EP (2)	EP3551651B1 (da)
JP (2)	JP6563614B1 (da)
KR (1)	KR102502040B1 (da)
CN (2)	CN117384274A (da)
AU (1)	AU2017371516C1 (da)
BR (1)	BR112019010624A2 (da)
CL (1)	CL2019001552A1 (da)
CO (1)	CO2019005924A2 (da)
DK (1)	DK3551651T3 (da)
ES (1)	ES2979184T3 (da)
IL (1)	IL266219B2 (da)
MX (1)	MX2019006486A (da)
PE (1)	PE20191083A1 (da)
RU (1)	RU2753193C2 (da)
SG (2)	SG10201911851VA (da)
WO (1)	WO2018104561A1 (da)
ZA (1)	ZA201902950B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
BR112022006546A2 (pt)	2019-10-07	2022-08-30	Kallyope Inc	Agonistas de gpr119
CA3173731A1 (en)	2020-02-28	2021-09-02	Kallyope, Inc.	Gpr40 agonists
EP4126003A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
WO2021198195A1 (en)	2020-03-30	2021-10-07	Zealand Pharma A/S	Agonist combination
CN116323608A (zh)	2020-05-19	2023-06-23	卡尔优普公司	Ampk活化剂
EP4172162A4 (en)	2020-06-26	2024-08-07	Kallyope, Inc.	AMPK ACTIVATORS
EP4259646A1 (en) *	2020-12-11	2023-10-18	IP2IPO Innovations Limited	Novel compounds
KR20230121822A (ko) *	2020-12-16	2023-08-21	질랜드 파마 에이/에스	Glp-1/glp-2 이중 효능제의 약학적 조성물
WO2022129311A1 (en) *	2020-12-16	2022-06-23	Zealand Pharma A/S	Pharmaceutical composition of glp-1/glp-2 dual agonists
AU2021401137B2 (en)	2020-12-16	2024-09-05	Zealand Pharma A/S	Pharmaceutical composition of glp-1/glp-2 dual agonists
EP4294424B1 (en)	2021-02-18	2026-02-11	Zealand Pharma A/S	Glp-1/glp-2 dual agonist for treating short bowel syndrome
AU2022339044A1 (en)	2021-09-03	2024-03-14	Zealand Pharma A/S	Dosage regime
CN118843639A (zh) *	2021-12-17	2024-10-25	白南生物技术有限公司	Gipr和glp2r的肽双重激动剂
WO2023132609A1 (ko) *	2022-01-05	2023-07-13	주식회사 휴온스랩	지속형 지방산-펩타이드 유도체 및 이의 용도
EP4212531A1 (en)	2022-01-14	2023-07-19	AGV Discovery	Azaindole derivatives and their use as erk kinase inhibitors
CN116655772A (zh) *	2022-02-18	2023-08-29	成都奥达生物科技有限公司	一种长效的glp-1/glp-2双激动剂化合物
IL319599A (en)	2022-09-19	2025-05-01	Zealand Pharma As	Combination therapy
EP4741420A1 (en) *	2023-06-30	2026-05-13	Huonslab Co., Ltd.	Pharmaceutical composition for preventing or treating obesity comprising glp analogue as active ingredient
KR20250075985A (ko) *	2023-11-22	2025-05-29	한도숙	상처 치료 또는 피부 주름형성 억제용 조성물
WO2025248124A1 (en)	2024-05-31	2025-12-04	Zealand Pharma A/S	Dapiglutide for use in treating a sub-group of subjects
WO2026052859A1 (en)	2024-09-09	2026-03-12	Zealand Pharma A/S	Treatment with dapiglutide
WO2026052861A1 (en)	2024-09-09	2026-03-12	Zealand Pharma A/S	Treatment with dapiglutide

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2844670A (en)	1953-12-30	1958-07-22	Morris Michael Marks	Rotary cam switches
US4288627A (en)	1980-02-12	1981-09-08	Phillips Petroleum Company	Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
CA2082279C (en)	1990-05-09	2007-09-04	Grethe Rasmussen	Cellulase preparation comprising an endoglucanase enzyme
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US5846747A (en)	1992-03-25	1998-12-08	Novo Nordisk A/S	Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da)	1992-03-25	1992-03-25	Bernard Thorens	Peptid
JP2961045B2 (ja)	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en)	1993-08-24	1995-03-21	Novo Nordisk A/S	Protracted glp-1
BR9407424A (pt)	1993-09-07	1996-04-09	Amylin Pharmaceuticals Inc	Métodos para regular motilidade gastrointestinal
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US6184208B1 (en)	1994-06-29	2001-02-06	Immunotech Developments Inc.	Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5789379A (en)	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US5523449A (en)	1995-05-17	1996-06-04	Bayer Corporation	Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
US5912229A (en)	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1975177T3 (da)	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
EP0906338B1 (en)	1996-04-12	2002-11-06	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
AU723694B2 (en)	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
DE69739172D1 (de)	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
JP3149958B2 (ja)	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US20020025933A1 (en)	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
EP0932614A1 (en)	1996-09-09	1999-08-04	Zealand Pharmaceuticals A/S	Peptide prodrugs containing an alpha-hydroxyacid linker
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5065198A (en)	1996-11-15	1998-06-10	Maria Grazia Masucci	Fusion proteins having increased half-lives
US5952301A (en)	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
PT1629849E (pt)	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
US6136784A (en)	1997-01-08	2000-10-24	Amylin Pharmaceuticals, Inc.	Amylin agonist pharmaceutical compositions containing insulin
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
CA2279836A1 (en)	1997-02-05	1998-08-13	1149336 Ontario Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en)	1997-03-03	1998-12-08	1149336 Ontario Inc.	Method of using exendin and GLP-1 to affect the central nervous system
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
TR199903120T2 (xx)	1997-05-07	2000-05-22	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften	Yeni sistein türevleri, bunların üretimi için işlemler ve bunları ihtiva eden farmasötik maddeler.
ES2210756T3 (es)	1997-05-16	2004-07-01	1149336 Ontario Inc.	Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
DK1019077T4 (da)	1997-08-08	2011-03-07	Amylin Pharmaceuticals Inc	Hidtil ukendte exendinagonistforbindelser
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
JP2001523688A (ja)	1997-11-14	2001-11-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	新規エキセンジン・アゴニスト化合物
US7220721B1 (en)	1997-11-14	2007-05-22	Amylin Pharmaceuticals, Inc.	Exendin agonist peptides
JP2003522721A (ja)	1997-11-14	2003-07-29	アミリン・ファーマシューティカルズ，インコーポレイテッド	新規なエキセンジンアゴニスト化合物
CA2312190A1 (en)	1997-12-05	1999-06-17	Eli Lilly And Company	Glp-1 formulations
EP2823812A1 (en)	1998-02-02	2015-01-14	Trustees Of Tufts College	Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
ATE366115T1 (de)	1998-02-13	2007-07-15	Amylin Pharmaceuticals Inc	Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE269103T1 (de)	1998-03-13	2004-07-15	Novo Nordisk As	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
WO1999049788A1 (en)	1998-03-30	1999-10-07	Focus Surgery, Inc.	Ablation system
AU7421598A (en)	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
JP4624558B2 (ja)	1998-08-10	2011-02-02	ザガバメントオブザユナイテッドステイツオブアメリカ，アズレプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
AU6294899A (en)	1998-10-07	2000-04-26	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1658856B1 (en)	1999-01-14	2010-03-17	Amylin Pharmaceuticals, Inc.	Exendins for glucagon suppression
US7399489B2 (en)	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
CN101181236A (zh)	1999-01-14	2008-05-21	安米林药品公司	新型exendin激动剂制剂及其给药方法
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en)	1999-03-17	2002-09-30	Novo Nordisk As	Method for acylating peptides and the glutaminic acid derivatives as acylating agents
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
US6271241B1 (en)	1999-04-02	2001-08-07	Neurogen Corporation	Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
EP1175443A1 (en)	1999-04-30	2002-01-30	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
WO2001041779A2 (en)	1999-12-08	2001-06-14	1149336 Ontario Inc.	Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002022151A2 (en)	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
ATE396202T1 (de)	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
JP2005506956A (ja)	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
EP1837031B1 (en)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Compositions and methods for treating diabetes
ES2327328T3 (es)	2002-07-04	2009-10-28	Zealand Pharma A/S	Glp-1 y procedimientos para el tratamiento de la diabetes.
BR0314996A (pt)	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004035624A2 (en)	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
WO2005019262A1 (en)	2003-08-21	2005-03-03	Novo Nordisk A/S	Purification of glucagon-like peptides
KR101241862B1 (ko)	2003-09-19	2013-03-13	노보 노르디스크 에이/에스	신규 ｇｌｐ-1 유도체
US7623530B2 (en)	2003-11-20	2009-11-24	Nokia Corporation	Indication of service flow termination by network control to policy decision function
US20090202494A1 (en)	2004-01-30	2009-08-13	Antonio Cruz	Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US20060094652A1 (en)	2004-02-11	2006-05-04	Levy Odile E	Hybrid polypeptides with selectable properties
WO2005082404A2 (en)	2004-02-27	2005-09-09	Novo Nordisk A/S	Glp-2 derivatives modified by lipophilic substituents
CN101010339B (zh) *	2004-07-02	2011-11-09	布里斯托尔-迈尔斯斯奎布公司	人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
US7847061B2 (en)	2004-11-01	2010-12-07	Nps Pharmaceuticals, Inc.	Treatment of short bowel syndrome patients with colon-in-continuity
MX2007013431A (es)	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
TW200716679A (en) *	2005-05-26	2007-05-01	Bristol Myers Squibb Co	N-terminally modified GLP-1 receptor modulators
RS51319B (sr) *	2005-09-22	2010-12-31	Biocompatibles Uk Limited	GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
WO2007095737A1 (en)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
EP2471810A1 (en)	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008071010A1 (en)	2006-12-12	2008-06-19	Waratah Pharmaceuticals Inc.	Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
MX2009008241A (es)	2007-02-15	2009-10-08	Univ Indiana Res & Tech Corp	Co-agonistas de receptor de glucagon/glp-1.
JP5385266B2 (ja)	2007-06-15	2014-01-08	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
GB2455553B (en)	2007-12-14	2012-10-24	Nuaire Ltd	Motor mounting assembly for an axial fan
TWI541023B (zh)	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
PL2370462T3 (pl)	2008-12-15	2015-01-30	Zealand Pharma As	Analogi glukagonu
AU2008365557A1 (en) *	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
EA020537B1 (ru)	2008-12-15	2014-11-28	Зилэнд Фарма А/С	Аналоги глюкагона
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
AP3329A (en) *	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
US20110312881A1 (en)	2009-12-21	2011-12-22	Amunix, Inc.	Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EA026384B1 (ru)	2010-01-20	2017-04-28	Зилэнд Фарма А/С	Лечение заболеваний сердца
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
US20130157954A1 (en) *	2010-05-11	2013-06-20	Nps Pharmaceuticals, Inc.	Methods for treatment or prophylaxis of kidney or liver dysfunction
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
KR20130086343A (ko) *	2010-06-24	2013-08-01	질랜드 파마 에이/에스	글루카곤 유사체
JP6033780B2 (ja) *	2010-10-15	2016-11-30	コーネル・ユニバーシティーＣｏｒｎｅｌｌＵｎｉｖｅｒｓｉｔｙ	内分泌障害、胃腸障害または自己免疫障害を処置するための組成物および方法
KR102011924B1 (ko)	2011-05-18	2019-08-21	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 제약
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
KR20140114845A (ko) *	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
TR201802689T4 (tr)	2012-05-03	2018-03-21	Zealand Pharma As	Glukagon benzeri peptit-2 (glp-2) analogları.
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345569B2 (en) *	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko) *	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
US20180280480A1 (en) *	2014-10-31	2018-10-04	Gubra Aps	Compositions and peptides having dual glp-1r and glp-2r agonist activity
WO2018104558A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
MX2019006600A (es)	2016-12-09	2019-08-01	Zealand Pharma As	Agonistas duales de glp-1/glp-2.
WO2018103868A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists

2017
- 2017-12-11 SG SG10201911851VA patent/SG10201911851VA/en unknown
- 2017-12-11 RU RU2019121253A patent/RU2753193C2/ru active
- 2017-12-11 BR BR112019010624-3A patent/BR112019010624A2/pt active Search and Examination
- 2017-12-11 PE PE2019001207A patent/PE20191083A1/es unknown
- 2017-12-11 AU AU2017371516A patent/AU2017371516C1/en active Active
- 2017-12-11 EP EP17832211.1A patent/EP3551651B1/en active Active
- 2017-12-11 CN CN202311177273.9A patent/CN117384274A/zh active Pending
- 2017-12-11 MX MX2019006486A patent/MX2019006486A/es unknown
- 2017-12-11 DK DK17832211.1T patent/DK3551651T3/da active
- 2017-12-11 ES ES17832211T patent/ES2979184T3/es active Active
- 2017-12-11 EP EP24154518.5A patent/EP4424320A3/en active Pending
- 2017-12-11 WO PCT/EP2017/082290 patent/WO2018104561A1/en not_active Ceased
- 2017-12-11 CN CN201780074629.2A patent/CN110088125B/zh active Active
- 2017-12-11 KR KR1020197019574A patent/KR102502040B1/ko active Active
- 2017-12-11 SG SG11201903938XA patent/SG11201903938XA/en unknown
- 2017-12-11 JP JP2018562339A patent/JP6563614B1/ja active Active
2018
- 2018-11-19 US US16/195,752 patent/US20190142904A1/en not_active Abandoned
2019
- 2019-04-24 IL IL266219A patent/IL266219B2/en unknown
- 2019-05-10 ZA ZA2019/02950A patent/ZA201902950B/en unknown
- 2019-06-06 CL CL2019001552A patent/CL2019001552A1/es unknown
- 2019-06-06 CO CONC2019/0005924A patent/CO2019005924A2/es unknown
- 2019-07-23 JP JP2019135379A patent/JP7009423B2/ja active Active
- 2019-08-19 US US16/544,535 patent/US10905745B2/en active Active
2020
- 2020-04-06 US US16/841,104 patent/US11395847B2/en active Active
2022
- 2022-06-07 US US17/834,062 patent/US20230405087A9/en active Pending

Also Published As

Publication number	Publication date
AU2017371516B2 (en)	2021-05-13
US10905745B2 (en)	2021-02-02
EP3551651A1 (en)	2019-10-16
ES2979184T3 (es)	2024-09-24
US11395847B2 (en)	2022-07-26
US20190365865A1 (en)	2019-12-05
JP2019525890A (ja)	2019-09-12
US20230405087A9 (en)	2023-12-21
IL266219B2 (en)	2023-05-01
US20200297818A1 (en)	2020-09-24
CN110088125B (zh)	2023-10-03
US20190142904A1 (en)	2019-05-16
EP3551651B1 (en)	2024-03-06
JP7009423B2 (ja)	2022-01-25
MX2019006486A (es)	2019-08-01
CA3043151A1 (en)	2018-06-14
CN110088125A (zh)	2019-08-02
CO2019005924A2 (es)	2019-08-30
JP6563614B1 (ja)	2019-08-21
AU2017371516A1 (en)	2019-05-23
WO2018104561A1 (en)	2018-06-14
CL2019001552A1 (es)	2020-01-03
SG10201911851VA (en)	2020-02-27
KR20190091335A (ko)	2019-08-05
IL266219A (en)	2019-06-30
ZA201902950B (en)	2024-09-25
KR102502040B1 (ko)	2023-02-24
PE20191083A1 (es)	2019-08-20
RU2019121253A (ru)	2021-01-12
IL266219B1 (en)	2023-01-01
RU2753193C2 (ru)	2021-08-12
BR112019010624A2 (pt)	2019-10-22
US20230000951A1 (en)	2023-01-05
AU2017371516C1 (en)	2021-09-02
RU2019121253A3 (da)	2021-01-21
EP4424320A2 (en)	2024-09-04
EP4424320A3 (en)	2025-06-11
US20210244798A9 (en)	2021-08-12
JP2019214583A (ja)	2019-12-19
NZ753010A (en)	2023-09-29
SG11201903938XA (en)	2019-05-30
CN117384274A (zh)	2024-01-12

Publication	Publication Date	Title
CY2023003I2 (el)	2023-06-09	Gip και glp-1 συν-αγωνιστικές ενώσεις
IL266219A (en)	2019-06-30	Acylated glp-1/glp-2 dual agonists
IL272232A (en)	2020-03-31	Glp-1 compositions and uses thereof
EP3385074A4 (en)	2019-10-30	MULTILAYER STRUCTURE
EP3549148A4 (en)	2020-07-29	COMPOSITE ELECTRODE
PL3303715T3 (pl)	2022-08-16	Rozkładany schron
EP3395868A4 (en)	2019-08-14	STRUCTURE
EP3449930C0 (en)	2025-04-02	SYNAPSE TRAINING AGENT
EP3435660A4 (en)	2019-10-30	HEAD-MOUNTED DISPLAY
EP3343603A4 (en)	2019-04-24	STRUCTURE
EP3466898A4 (en)	2020-01-22	Laminated glass
EP3437786A4 (en)	2019-05-08	Joint structure
PL3408472T3 (pl)	2023-03-13	Składana konstrukcja
EP3491255A4 (en)	2020-04-08	IMPROVED TELESCOPIC MECHANISM
UA34707S (uk)	2017-06-26	Всюдихід
EP3563586A4 (en)	2020-09-16	INSERTION EXTRACTION STRUCTURE
EP3437147C0 (en)	2025-05-14	CONDUCTIVE COMPOSITES
DK3310756T3 (da)	2021-03-08	Thromboxanreceptorantagonister
EP3454107A4 (en)	2020-02-19	HEAD MOUNTED DISPLAY
DK3280853T3 (da)	2019-07-22	Holdemekanisme
ES2543256B1 (es)	2016-05-26	Estructura espacial
EP3556555A4 (en)	2019-11-06	MULTILAYER STRUCTURE
EP3639293A4 (en)	2020-06-10	MULTILAYERED STRUCTURE
DK3257589T3 (da)	2020-03-16	Dyse
EP3551615A4 (en)	2020-07-29	SCALABLE POLYPROPIONATE LACTONE STEREOTETRADES